Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

Publication date: July 2021Source: The Lancet Neurology, Volume 20, Issue 7Author(s): James F Howard, Vera Bril, Tuan Vu, Chafic Karam, Stojan Peric, Temur Margania, Hiroyuki Murai, Malgorzata Bilinska, Roman Shakarishvili, Marek Smilowski, Antonio Guglietta, Peter Ulrichts, Tony Vangeneugden, Kimiaki Utsugisawa, Jan Verschuuren, Renato Mantegazza, Jan De Bleeker, Kathy De Koning, Katrien De Mey, Annelien De Pue
Source: The Lancet Neurology - Category: Neurology Source Type: research